Amylyx Pharmaceuticals, INC. (AMLX) — SEC Filings

Overview

Amylyx Pharmaceuticals, INC. (AMLX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 23, 2026: Amylyx Pharmaceuticals, Inc. filed its Annual Report to Security Holders (ARS) on April 23, 2026, for the period ending December 31, 2025. The filing includes the complete submission text file and the ARS document itself. The company's principal executive offices are located at 55 Cambridge Parkway,

Sentiment Summary

Across 38 filings, the sentiment breakdown is: 3 bullish, 2 bearish, 33 neutral. The dominant filing sentiment for Amylyx Pharmaceuticals, INC. is neutral.

Filing Type Overview

Amylyx Pharmaceuticals, INC. (AMLX) has filed 1 ARS, 1 DEFA14A, 15 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 6 SC 13G/A, 5 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (38)

• Amylyx Pharmaceuticals Files Annual Report — ARS · Apr 23, 2026 Risk: low
  Amylyx Pharmaceuticals, Inc. filed its Annual Report to Security Holders (ARS) on April 23, 2026, for the period ending December 31, 2025. The filing includes t
• Amylyx Pharmaceuticals Files DEFA14A Proxy Materials — DEFA14A · Apr 23, 2026 Risk: low
  Amylyx Pharmaceuticals, Inc. filed a Definitive Additional Materials (DEFA14A) on April 23, 2026. This filing is related to proxy materials and does not contain
• Amylyx Files 8-K, Discloses New Info via Reg FD on March 24, 2026 — 8-K · Mar 24, 2026
  Amylyx Pharmaceuticals, Inc. filed an 8-K on March 24, 2026, under Item 7.01 Regulation FD Disclosure, indicating they are publicly disclosing information that
• Amylyx Shifts Focus Amidst Zero Revenue, Bolsters Cash by $147M — 10-Q · Nov 6, 2025 Risk: high
  Amylyx Pharmaceuticals, Inc. (AMLX) reported a significant net loss of $111.7 million for the nine months ended September 30, 2025, a substantial improvement fr
• Amylyx Pharmaceuticals Files 8-K — 8-K · Sep 10, 2025 Risk: low
  Amylyx Pharmaceuticals, Inc. filed an 8-K on September 10, 2025, reporting an entry into a material definitive agreement and financial statements/exhibits. The
• Amylyx Pharmaceuticals Files 8-K — 8-K · Aug 27, 2025 Risk: medium
  Amylyx Pharmaceuticals, Inc. filed an 8-K on August 27, 2025, to report other events. The filing does not contain specific details about the nature of these eve
• Amylyx's Net Loss Widens to $100.2M Despite 25% Revenue Growth — 10-Q · Aug 7, 2025 Risk: high
  Amylyx Pharmaceuticals, Inc. reported a net loss of $100.2 million for the six months ended June 30, 2025, a significant increase from the $75.8 million net los
• Amylyx Pharmaceuticals Files 8-K on Financials — 8-K · Aug 7, 2025 Risk: low
  Amylyx Pharmaceuticals, Inc. filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition. The filing includes financial state
• Amylyx Pharmaceuticals Files 8-K on Security Holder Votes — 8-K · Jun 5, 2025 Risk: low
  Amylyx Pharmaceuticals, Inc. filed an 8-K on June 5, 2025, to report on the submission of matters to a vote of security holders. The filing does not contain spe
• Amylyx Pharmaceuticals Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: medium
  Amylyx Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and operations, including de
• Amylyx Pharma DEF 14A: Executive Compensation Details — DEF 14A · Apr 24, 2025 Risk: low
  Amylyx Pharmaceuticals, Inc. filed its DEF 14A on April 24, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, inclu
• Amylyx Pharmaceuticals Files 2024 10-K — 10-K · Mar 4, 2025 Risk: medium
  Amylyx Pharmaceuticals, Inc. filed its 2024 10-K on March 4, 2025, reporting on its fiscal year ending December 31, 2024. The company, based in Cambridge, MA, o
• Amylyx Pharmaceuticals Files 8-K — 8-K · Jan 10, 2025 Risk: medium
  Amylyx Pharmaceuticals, Inc. filed an 8-K on January 10, 2025, reporting the entry into a material definitive agreement and the filing of financial statements a
• Amylyx Pharmaceuticals Files 8-K Report — 8-K · Dec 30, 2024 Risk: low
  On December 30, 2024, Amylyx Pharmaceuticals, Inc. filed an 8-K report. The filing indicates it is a current report pursuant to Section 13 or 15(d) of the Secur
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• Amylyx Pharmaceuticals Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
  Amylyx Pharmaceuticals, Inc. filed its quarterly report for the period ending September 30, 2024. The company's financial statements and disclosures are present
• SC 13G Filing — SC 13G · Nov 4, 2024
• SC 13G Filing — SC 13G · Oct 25, 2024
• Amylyx Pharmaceuticals Files 8-K — 8-K · Oct 17, 2024 Risk: medium
  Amylyx Pharmaceuticals, Inc. filed an 8-K on October 17, 2024, to report other events. The filing does not contain specific details about the nature of these ev
• SC 13G Filing — SC 13G · Aug 26, 2024
• Amylyx Pharmaceuticals Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
  Amylyx Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and business updates. Key financial
• Amylyx Acquires Knopp Neurosciences, Expands ALS Pipeline — 8-K · Jul 10, 2024 Risk: medium
  Amylyx Pharmaceuticals, Inc. announced on July 9, 2024, the completion of its acquisition of 100% of the outstanding shares of privately held Knopp Neuroscience
• SC 13G/A Filing — SC 13G/A · Jul 8, 2024
• Amylyx Pharmaceuticals Files 8-K for Material Agreement — 8-K · Jun 21, 2024 Risk: medium
  On June 21, 2024, Amylyx Pharmaceuticals, Inc. filed an 8-K to report the entry into a material definitive agreement. The filing does not disclose specific deta
• Amylyx Pharmaceuticals Files 8-K on Security Holder Vote Matters — 8-K · Jun 6, 2024 Risk: low
  Amylyx Pharmaceuticals, Inc. filed an 8-K on June 6, 2024, to report on the submission of matters to a vote of its security holders. The filing does not disclos
• Amylyx Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: low
  Amylyx Pharmaceuticals, Inc. (AMLX) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Amylyx Pharmaceuticals, Inc. filed a 10-Q report for the period
• Amylyx Pharmaceuticals, Inc. DEF 14A Filing — DEF 14A · Apr 24, 2024 Risk: low
  Amylyx Pharmaceuticals, Inc. (AMLX) filed a Proxy Statement (DEF 14A) with the SEC on April 24, 2024. Filing type is DEF 14A, filed on 2024-04-24. Company name
• Cooper Companies to Acquire Amylyx Pharma for $2.8B — 8-K · Apr 10, 2024 Risk: medium
  Amylyx Pharmaceuticals, Inc. announced on April 10, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of The Cooper Companies
• Amylyx Pharmaceuticals Files 8-K on Exit/Disposal Activities — 8-K · Apr 4, 2024 Risk: medium
  Amylyx Pharmaceuticals, Inc. filed an 8-K on April 4, 2024, reporting on events that occurred on April 3, 2024. The filing indicates costs associated with exit
• Amylyx Pharmaceuticals Appoints New Directors, Updates Executive Compensation — 8-K · Mar 14, 2024 Risk: low
  Amylyx Pharmaceuticals, Inc. announced on March 14, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two ne
• SC 13G Filing — SC 13G · Mar 11, 2024
• Amylyx Pharmaceuticals Files 8-K — 8-K · Mar 8, 2024 Risk: low
  Amylyx Pharmaceuticals, Inc. filed an 8-K on March 8, 2024, to report on other events and potentially financial statements and exhibits. The filing does not det
• Amylyx Pharmaceuticals, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 22, 2024 Risk: medium
  Amylyx Pharmaceuticals, Inc. (AMLX) filed a Annual Report (10-K) with the SEC on February 22, 2024. Amylyx Pharmaceuticals, Inc. filed its 2023 Annual Report on
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• BlackRock Discloses 5.0% Stake in Amylyx Pharmaceuticals — SC 13G · Jan 29, 2024
  BlackRock Inc., a major investment firm, reported on January 29, 2024, that as of December 31, 2023, it holds a significant stake in Amylyx Pharmaceuticals, Inc

Risk Profile

Risk Assessment: Of AMLX's 26 recent filings, 2 were flagged as high-risk, 12 as medium-risk, and 12 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Amylyx Pharmaceuticals, INC.'s most recent 10-Q filing (Nov 6, 2025):

• Revenue: $0
• Net Income: -$111.7 million
• EPS: N/A
• Debt-to-Equity: 0.09
• Cash Position: $225.2 million
• Operating Margin: N/A
• Total Assets: $362.7 million
• Total Debt: $30.7 million

Key Executives

• Joshua Cohen
• Justin Klee
• Dr. Albert Eschenmoser
• Dr. David J. Ebersman
• Joshua Allen
• Dr. Sabrina Paganoni

Industry Context

The biopharmaceutical industry, particularly in the neurodegenerative disease space, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Amylyx are focused on developing novel therapies for unmet medical needs, often requiring substantial capital investment. The competitive landscape is intense, with both large pharmaceutical companies and smaller biotech firms vying for market share and therapeutic breakthroughs.

Top Tags

pharmaceuticals (5) · financials (4) · 10-Q (4) · filing (3) · Biotechnology (3) · material-agreement (3) · 8-K (3) · regulatory-filing (3) · corporate-governance (3) · Amylyx Pharmaceuticals (3)

Key Numbers

• Product Revenue, Net: $0 — Represents a complete cessation of product sales for the nine months ended September 30, 2025, down from $88.0 million in 2024.
• Net Loss: $111.7 million — Improved from $264.2 million in the prior year, primarily due to the absence of large impairment charges.
• Cash and Cash Equivalents: $225.2 million — Increased significantly from $77.4 million at year-end 2024, providing liquidity for R&D.
• Proceeds from Financings: $256.7 million — Key driver of the increased cash balance, indicating successful capital raises.
• Research and Development Expenses: $69.2 million — Decreased from $81.2 million, reflecting ongoing investment in pipeline candidates.
• Selling, General and Administrative Expenses: $47.5 million — Significantly reduced from $97.2 million, aligning with the shift away from commercialization.
• Accumulated Deficit: $718.4 million — Increased from $606.7 million, indicating continued losses despite improved net loss.
• Shares Issued and Outstanding: 109,766,382 — Increased from 68,629,738 shares, reflecting dilution from recent financings.
• Commission File Number: 001-41199 — Identifier for the company's SEC filings
• IRS Employer Identification No.: 46-4600503 — Tax identification number for the company
• AMX0035 Revenue: $150.5M — for six months ended June 30, 2025, up 25.1% from $120.3M
• Research and Development Expense: $45.1M — for six months ended June 30, 2025, decreased 19.0% from $55.7M
• Selling, General, and Administrative Expenses: $125.8M — for six months ended June 30, 2025, increased 19.6% from $105.2M
• Revenue Growth: 25.1% — increase in AMX0035 revenue for the six months ended June 30, 2025
• R&D Expense Decrease: 19.0% — reduction in research and development expenses for the six months ended June 30, 2025

Related Companies

AMYX · COO

Frequently Asked Questions